Health
Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies – News-Medical.Net
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-ca…
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.
According to WHO reports, the current COVID-19 (coronavirus disease 2019) pandemic has caused more…
-
Noosa News16 hours agoPrincess Anne visits Gallipoli Barracks in Brisbane on Remembrance Day as Australian tour ends
-
Noosa News14 hours agoRoyal visit to Gallipoli Barracks in Enoggera on Remembrance Day
-
General16 hours ago‘Do you care?’: Coles stares down anti-salmon activists
-
General12 hours agoCar bomb outside Islamabad court kills at least five, Pakistani media says